Fibrinogen and von Willebrand factor (Fbg/vWF)

Fibrinogen and von Willebrand factor (vWF) are essential plasma glycoproteins involved in the complex process of hemostasis and blood coagulation (StatPearls, 2023). Fibrinogen, also known as Coagulation Factor I, is synthesized in the liver and converted by thrombin into fibrin, which forms the structural network of a blood clot (NCBI, 2022). von Willebrand factor is a large multimeric protein produced by endothelial cells and megakaryocytes that facilitates platelet adhesion to the vascular subendothelium and stabilizes Factor VIII (UniProt P04275). Both proteins act as key ligands for the platelet integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor, a critical step in platelet aggregation (PubMed, 11007015). Deficiencies or defects in these proteins result in bleeding disorders like von Willebrand disease or afibrinogenemia, while excessive activity contributes to arterial thrombosis and cardiovascular disease (NIH, 2023). Pharmacological interventions include replacement therapies (e.g., fibrinogen concentrates), vWF-specific inhibitors like caplacizumab, and GPIIb/IIIa antagonists that prevent the binding of both proteins to platelets to treat acute coronary syndromes (FDA, 2019).

Other names

Factor IvWFFGAFGBFGGVWFvon Willebrand antigen IIFibrinogen alpha chainFibrinogen beta chainFibrinogen gamma chainFibrinogenvon Willebrand factor

The mechanism of action involves either the replacement of these proteins in deficiency states or the inhibition of their function to prevent thrombosis. Caplacizumab is a nanobody that binds the vWF A1 domain, blocking its interaction with platelet glycoprotein Ib-IX-V. Additionally, GPIIb/IIIa inhibitors like abciximab and eptifibatide prevent platelet aggregation by blocking the binding of both fibrinogen and vWF to the integrin alpha-IIb/beta-3 receptor (StatPearls, 2023; FDA, 2019).